Clinical trials: Relapsed/Refractory Small Cell Lung Cancer
Lung Cancer
Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer
The purpose of this study is to determine whether treatment with temozolomide will shrink small cell lung cancer tumors. Temozolomide is an oral chemotherapy drug that is currently used to treat brain cancer and melanoma.
- Trial name
- NCT00740636
- Testing
- Temozolomide
- Where
- 5 sites in United States
- Volunteers
- 92 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Small Cell Lung Cancer
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of aldoxorubicin compared to topotecan in subjects with metastatic small cell lung cancer.
- Trial name
- NCT02200757
- Testing
- Aldoxorubicin, Topotecan
- Where
- 29 sites in United States, Hungary and 1 more
- Volunteers
- 135 people
- Sponsor
- ImmunityBio, Inc.
Small Cell Lung Cancer
Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
This was a 2-arm, open-label, phase 2 study of pegylated arginine deiminase (ADI-PEG) 20 in subjects with relapsed sensitive or refractory small cell lung cancer (SCLC).
- Trial name
- NCT01266018
- Testing
- ADI-PEG 20 (Arginine deiminase pegylated)
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 22 people
- Sponsor
- Ludwig Institute for Cancer Research
Lung Cancer
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00754923
- Testing
- sorafenib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Small Cell Lung Cancer
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer
The purpose of this study is to determine the efficacy of rovalpituzumab tesirine as a third-line and later treatment for participants with relapsed or refractory delta-like protein 3 (DLL3) expressing small cell lung cancer…
- Trial name
- TRINITY (NCT02674568)
- Testing
- Rovalpituzumab tesirine
- Volunteers
- 342 people
- Sponsor
- AbbVie
Cancer, Carcinoma, Non-Small Cell Lung
BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)
The purpose of the study is to evaluate if BAY43-9006 has an effect on the tumors, how long the effect continues, if the patients receiving BAY43-9006 will live longer.
- Trial name
- NCT00101413
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 2 sites in United States, Germany
- Volunteers
- 52 people
- Sponsor
- Bayer
Multiple Myeloma, Solid Tumors
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
The purpose of this trial is to characterize the safety and toxicity of DKN-01 by determining a maximum-tolerated dose and associated dose limiting toxicity. To evaluate the pharmacodynamic response in patients with cancer.
- Conditions
- Multiple Myeloma, Solid Tumors, Non-Small Cell Lung Cancer
- Trial name
- NCT01457417
- Testing
- DKN-01
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Leap Therapeutics, Inc.
Recurrent Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors
This phase I/II trial is studying the side effects and best dose of obatoclax mesylate when given together with topotecan hydrochloride and to see how well they work in treating patients with relapsed or refractory small cell…
- Trial name
- NCT00521144
- Testing
- obatoclax mesylate, topotecan hydrochloride, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
This phase II trial is studying how well etanercept works in treating young patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
- Trial name
- NCT00309907
- Testing
- etanercept, methylprednisolone
- Where
- 26 sites in United States
- Volunteers
- 39 people
- Sponsor
- Children's Oncology Group
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer
- Trial name
- MDX1106-01 (NCT00441337)
- Testing
- MDX-1106
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Any Advanced Solid Tumors, Triple Negative Breast Cancer
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
The main purposes of Phase 1b of this study are to determine the following in participants with advanced solid tumors: Safety and tolerability of NT-I7 in combination with pembrolizumab Maximum Tolerated Dose (MTD) and/or the…
- Conditions
- Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT04332653
- Testing
- NT-I7, pembrolizumab (KEYTRUDA®)
- Where
- 8 sites in United States
- Volunteers
- 215 people
- Sponsor
- NeoImmuneTech
Lung Cancer
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00984542
- Testing
- bendamustine hydrochloride
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Carcinoma, Non-Small-Cell Lung
A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).
The purpose of the study is to see if sorafenib plus best supportive care (i.e. in addition to the non-cancer treatments patients would normally receive) is an effective treatment for lung cancer compared to best supportive care…
- Trial name
- MISSION (NCT00863746)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 182 sites in United States, Argentina and 32 more
- Volunteers
- 703 people
- Sponsor
- Bayer
Hematologic Malignancies, Solid Tumor
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
- Trial name
- NCT02663518
- Testing
- PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
- Where
- 51 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Pfizer
Solid Tumors
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
The purpose of this study is to determine the safety and tolerability of ME-344 when given in combination with Hycamtin® in patients with solid tumors
- Trial name
- NCT02100007
- Testing
- ME-344, Topotecan
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 46 people
- Sponsor
- MEI Pharma, Inc.
Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
The purpose of the study is to evaluate whether treatment with ibrutinib as a monotherapy results in a clinically significant improvement in progression free survival (PFS) as compared to treatment with ofatumumab in patients…
- Trial name
- RESONATE™ (NCT01578707)
- Testing
- ofatumumab, ibrutinib
- Where
- 76 sites in United States, Australia and 8 more
- Volunteers
- 391 people
- Sponsor
- Pharmacyclics LLC.
Small Cell Lung Cancer
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer
This is a 2-part, multicenter, open-label, randomized study of dinutuximab and irinotecan versus irinotecan alone in subjects with relapsed or refractory small cell lung cancer (SCLC).
- Trial name
- NCT03098030
- Testing
- Dinutuximab, Irinotecan, Topotecan
- Where
- 226 sites in United States, Australia and 21 more
- Volunteers
- 483 people
- Sponsor
- United Therapeutics
Carcinoma, Non-Small-Cell Lung
Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer
Background: The drug pemetrexed is used to treat non-small cell lung cancer (NSCLC) that does not respond to standard therapy or that has recurred after standard therapy; however, only 9 in 100 patients respond to pemetrexed.
- Trial name
- NCT00923273
- Testing
- FDG-PET, Pemetrexed, Sirolimus
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Malignant Solid Neoplasm, Recurrent Lung Small Cell Carcinoma
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
This phase I/II trial studies the best dose and side effects of navitoclax and how well it works when given together with vistusertib in treating patients with small cell lung cancer and solid tumors that have come back…
- Conditions
- Metastatic Malignant Solid Neoplasm, Recurrent Lung Small Cell Carcinoma, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
- Trial name
- NCT03366103
- Testing
- Navitoclax, Vistusertib
- Where
- 14 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Lung Small Cell Carcinoma
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
This randomized phase II trial studies how well temozolomide with or without veliparib works in treating patients with small cell lung cancer that has returned or does not respond to treatment.
- Trial name
- NCT01638546
- Testing
- Laboratory Biomarker Analysis, Temozolomide, Veliparib
- Where
- 14 sites in United States
- Volunteers
- 97 people
- Sponsor
- National Cancer Institute (NCI)